# EBRT + Lu-PSMA for N1M0 Prostate Cancer

> **NCT05162573** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 14 (actual)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** 177Lu-PSMA-617
- **RADIATION:** EBRT

## Key facts

- **NCT ID:** NCT05162573
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162573, "EBRT + Lu-PSMA for N1M0 Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05162573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*